This week’s biotechnology news headlines include, California’s controversial vaccine bill, brain scan to evaluate autism outcomes, Sanofi’s plans for Dengue vaccine roll out, BMS investing in Gene Therapy company, ovarian cancer drug receives FDA Breakthrough designation, Caribou Bio raises 11M for gene editing technology, and stem cells can be manipulated to promote bone growth.
Cord Blood World Europe Congress 2015 – May 20-21, 2015 – Business Design Centre, London, UK Build deposits, reduce costs, retain quality, decrease volume and increase utilization.
“A bill that would eliminate personal-belief exemptions from vaccine requirements passed a state health panel amid impassioned pleas from parents, doctors and activist Robert Kennedy Jr. Under the proposal, which Wednesday passed the state Senate Health Committee on a 6-2 vote, exemptions would be available only for children with health problems.”
If you like this story, please see our blog titled “The Evolution of Vaccine Manufacturing – Past, Current, and Future Trends”
“Brain scans of possibly autistic infants and toddlers can predict whether they will develop normal language skills, according to a new study by UC San Diego researchers.”
If you like this story, please see our blog titled “2014 FDA New Drug Approvals – 11 Biologics Receive Approval“
“After the company’s largest investment ever in the development of a vaccine, Sanofi Pasteur’s dengue vaccine launch is set for this year, and it’ll be closely watched as the group introduces the jab in a manner reversed from traditional launches.”
If you like this story, please see our blog titled “10 Biologics on Best Selling Drugs List for 2014”
“Bristol-Myers Squibb Co said it would invest in Dutch biotech uniQure NV, joining other big drugmakers who have moved to gain a foothold in the promising Gene Therapy market.”
If you like this story, please see our blog titled “Materials and Assay Systems Used for 3D Cell Culture”
“Caribou Biosciences, one of the biotech startups working to advance a much-watched new technology for precise gene editing, announced today it has raised an $11 million Series A round from venture capital firms and Swiss drug giant Novartis.”
If you like this story, please see our blog titled “Cell Therapy: Are we there yet?”